Skip to content

Celcuity CELC Payment-in-kind interest

Payment-in-kind interest at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:PaidInKindInterest.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's payment-in-kind interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's payment-in-kind interest?
Celcuity (CELC) reported payment-in-kind interest of $325K in Q1 2026.
How has Celcuity's payment-in-kind interest changed year-over-year?
Celcuity's payment-in-kind interest increased by 30.5% year-over-year, from $249K to $325K.
What is the long-term trend for Celcuity's payment-in-kind interest?
Over 3 years (2022 to 2025), Celcuity's payment-in-kind interest has grown at a 34.4% compound annual growth rate (CAGR), from $455.07K to $1.1M.
What does payment-in-kind interest mean?
Represents interest expense that is settled by issuing additional debt or equity instruments rather than through cash payments. This metric is critical for assessing how a company manages its debt obligations without immediate cash outflows, which is common in capital-intensive clinical-stage biotechnology firms.